Adaptive Biotechnologies Executive Sells Shares Amid Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy ADPT?
Source: Fool
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 on April 1 and 2, 2026, indicating a liquidity event amidst strong company performance.
- Ownership Analysis: The sale represents 7.85% of Rubinstein's direct holdings, leaving her with 447,202 shares post-transaction, which underscores her ongoing investment and alignment with shareholder interests.
- Financial Performance Highlights: The company reported $276.98 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment contributing over three-quarters of total sales, showcasing strong growth potential in personalized medicine.
- Profitability Outlook: While the company posted a net loss of $59.5 million, this is an improvement from $159.6 million the previous year, and management anticipates continued MRD growth in 2026, indicating progress towards broader profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.470
Low
20.00
Averages
20.86
High
22.00
Current: 14.470
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
Adaptive Biotechnologies Executive Stock Sale
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of Common Stock in open-market transactions from April 14 to 16, 2026, totaling approximately $826,000, which represents a 12.29% reduction in her direct holdings to 408,160 shares.
- Sale Context: The shares sold were acquired through the exercise of options at a weighted average price of around $14.45 per share, despite a market close price of $14.08, indicating that the sale may be more about supplementing income rather than a lack of confidence in the company's future.
- Holding Structure Change: During the four-day period from April 9 to 13, Rubinstein also reduced her direct holdings by 27,736 shares, yet she still retains 408,160 shares and 148,770 stock options, aligning her interests with those of shareholders.
- Growth Potential: Revenue from Adaptive Biotechnologies' minimal residual disease monitoring services rose 46% last year, and the business is poised for further growth in 2026, particularly after receiving expanded Medicare coverage for mantle cell lymphoma patients, highlighting the company's market potential in cancer monitoring.
See More
Adaptive Biotechnologies Executive Sells Shares
- Transaction Overview: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of common stock in open-market transactions between April 14 and 16, 2026, totaling approximately $826,000, indicating a liquidity need from the executive.
- Impact on Holdings: Following the sale, Rubinstein's direct ownership decreased by 12.29%, leaving her with 408,160 shares, suggesting that future transactions may be constrained by the reduced share count, potentially affecting her influence over the company.
- Transaction Context: The sale involved the exercise of 44,166 options for common stock, with all resulting shares sold immediately, demonstrating a liquidity event rather than a long-term holding disposition, reflecting the executive's financial obligations.
- Company Performance Outlook: Despite the insider selling, Adaptive Biotechnologies' revenue from minimal residual disease (MRD) cancer monitoring services rose 46% last year and is poised for further growth in 2026, highlighting the company's market potential and future growth opportunities.
See More
Adaptive Biotechnologies Executive Sells Shares Amid Strong Revenue Growth
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 on April 1 and 2, 2026, indicating a liquidity event amidst strong company performance.
- Ownership Analysis: The sale represents 7.85% of Rubinstein's direct holdings, leaving her with 447,202 shares post-transaction, which underscores her ongoing investment and alignment with shareholder interests.
- Financial Performance Highlights: The company reported $276.98 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment contributing over three-quarters of total sales, showcasing strong growth potential in personalized medicine.
- Profitability Outlook: While the company posted a net loss of $59.5 million, this is an improvement from $159.6 million the previous year, and management anticipates continued MRD growth in 2026, indicating progress towards broader profitability.
See More
Adaptive Biotechnologies Executive Sells Shares
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 between April 1 and 2, 2026, at an average price of $14.53 per share, indicating a liquidity need among executives.
- Holding Reduction: This transaction reduced Rubinstein's direct holdings by 7.85% to 447,202 shares, reflecting stock movements under a pre-arranged 10b5-1 plan, which may not necessarily indicate a negative outlook on the company's future.
- Performance Growth: Adaptive Biotechnologies reported $277 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment accounting for over three-quarters of total sales, growing 46% and achieving positive adjusted EBITDA, marking a significant step towards profitability.
- Future Outlook: While insider selling is often seen as a liquidity event, management anticipates continued growth in the MRD segment for 2026, prompting investors to focus on whether Adaptive can convert its strong revenue growth into sustained profitability.
See More
Adaptive Biotechnologies Executive Sells Shares Worth $1.21 Million
- Transaction Overview: Julie Rubinstein, COO of Adaptive Biotechnologies, disclosed the sale of 81,342 shares for approximately $1.21 million in an SEC Form 4 filing on March 10, 2026, reflecting executive liquidity management amid rising stock prices.
- Ownership Change Analysis: The transaction reduced Rubinstein's direct holdings by 11.22%, leaving her with 643,471 shares; despite this reduction, she retains over 510,000 vested options, maintaining a relatively stable equity exposure.
- Market Environment Impact: At the time of the sale, Adaptive Biotechnologies shares were priced around $14.90, with a 118% increase over the past year, providing a favorable backdrop for executive liquidity events, although shares have recently cooled, still up over 50% year-over-year.
- Business Outlook: Adaptive's core product, clonoSEQ, achieved 46% revenue growth in 2025 and reached profitability, with guidance for positive adjusted EBITDA and free cash flow by year-end 2026, marking a significant inflection point for a company that lost $80 million on an adjusted basis just two years prior.
See More
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
Adaptive Biotechnologies Executive Stock Sale
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of Common Stock in open-market transactions from April 14 to 16, 2026, totaling approximately $826,000, which represents a 12.29% reduction in her direct holdings to 408,160 shares.
- Sale Context: The shares sold were acquired through the exercise of options at a weighted average price of around $14.45 per share, despite a market close price of $14.08, indicating that the sale may be more about supplementing income rather than a lack of confidence in the company's future.
- Holding Structure Change: During the four-day period from April 9 to 13, Rubinstein also reduced her direct holdings by 27,736 shares, yet she still retains 408,160 shares and 148,770 stock options, aligning her interests with those of shareholders.
- Growth Potential: Revenue from Adaptive Biotechnologies' minimal residual disease monitoring services rose 46% last year, and the business is poised for further growth in 2026, particularly after receiving expanded Medicare coverage for mantle cell lymphoma patients, highlighting the company's market potential in cancer monitoring.
See More
Adaptive Biotechnologies Executive Sells Shares
- Transaction Overview: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of common stock in open-market transactions between April 14 and 16, 2026, totaling approximately $826,000, indicating a liquidity need from the executive.
- Impact on Holdings: Following the sale, Rubinstein's direct ownership decreased by 12.29%, leaving her with 408,160 shares, suggesting that future transactions may be constrained by the reduced share count, potentially affecting her influence over the company.
- Transaction Context: The sale involved the exercise of 44,166 options for common stock, with all resulting shares sold immediately, demonstrating a liquidity event rather than a long-term holding disposition, reflecting the executive's financial obligations.
- Company Performance Outlook: Despite the insider selling, Adaptive Biotechnologies' revenue from minimal residual disease (MRD) cancer monitoring services rose 46% last year and is poised for further growth in 2026, highlighting the company's market potential and future growth opportunities.
See More
Adaptive Biotechnologies Executive Sells Shares Amid Strong Revenue Growth
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 on April 1 and 2, 2026, indicating a liquidity event amidst strong company performance.
- Ownership Analysis: The sale represents 7.85% of Rubinstein's direct holdings, leaving her with 447,202 shares post-transaction, which underscores her ongoing investment and alignment with shareholder interests.
- Financial Performance Highlights: The company reported $276.98 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment contributing over three-quarters of total sales, showcasing strong growth potential in personalized medicine.
- Profitability Outlook: While the company posted a net loss of $59.5 million, this is an improvement from $159.6 million the previous year, and management anticipates continued MRD growth in 2026, indicating progress towards broader profitability.
See More
Adaptive Biotechnologies Executive Sells Shares
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 38,120 shares of common stock for approximately $554,000 between April 1 and 2, 2026, at an average price of $14.53 per share, indicating a liquidity need among executives.
- Holding Reduction: This transaction reduced Rubinstein's direct holdings by 7.85% to 447,202 shares, reflecting stock movements under a pre-arranged 10b5-1 plan, which may not necessarily indicate a negative outlook on the company's future.
- Performance Growth: Adaptive Biotechnologies reported $277 million in revenue for 2025, a 55% year-over-year increase, with the MRD segment accounting for over three-quarters of total sales, growing 46% and achieving positive adjusted EBITDA, marking a significant step towards profitability.
- Future Outlook: While insider selling is often seen as a liquidity event, management anticipates continued growth in the MRD segment for 2026, prompting investors to focus on whether Adaptive can convert its strong revenue growth into sustained profitability.
See More
Adaptive Biotechnologies Executive Sells Shares Worth $1.21 Million
- Transaction Overview: Julie Rubinstein, COO of Adaptive Biotechnologies, disclosed the sale of 81,342 shares for approximately $1.21 million in an SEC Form 4 filing on March 10, 2026, reflecting executive liquidity management amid rising stock prices.
- Ownership Change Analysis: The transaction reduced Rubinstein's direct holdings by 11.22%, leaving her with 643,471 shares; despite this reduction, she retains over 510,000 vested options, maintaining a relatively stable equity exposure.
- Market Environment Impact: At the time of the sale, Adaptive Biotechnologies shares were priced around $14.90, with a 118% increase over the past year, providing a favorable backdrop for executive liquidity events, although shares have recently cooled, still up over 50% year-over-year.
- Business Outlook: Adaptive's core product, clonoSEQ, achieved 46% revenue growth in 2025 and reached profitability, with guidance for positive adjusted EBITDA and free cash flow by year-end 2026, marking a significant inflection point for a company that lost $80 million on an adjusted basis just two years prior.
See More
